BCYC
Price
$7.12
Change
-$0.20 (-2.74%)
Updated
Jun 25, 04:59 PM (EDT)
Capitalization
506.25M
36 days until earnings call
INO
Price
$2.21
Change
+$0.27 (+13.99%)
Updated
Jun 25, 04:59 PM (EDT)
Capitalization
75.55M
Interact to see
Advertisement

BCYC vs INO

Header iconBCYC vs INO Comparison
Open Charts BCYC vs INOBanner chart's image
Bicycle Therapeutics
Price$7.12
Change-$0.20 (-2.74%)
Volume$6.8K
Capitalization506.25M
Inovio Pharmaceuticals
Price$2.21
Change+$0.27 (+13.99%)
Volume$4.89K
Capitalization75.55M
BCYC vs INO Comparison Chart in %
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. INO commentary
Jun 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and INO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 25, 2025
Stock price -- (BCYC: $7.31 vs. INO: $2.06)
Brand notoriety: BCYC: Not notable vs. INO: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 95% vs. INO: 93%
Market capitalization -- BCYC: $506.25M vs. INO: $75.55M
BCYC [@Biotechnology] is valued at $506.25M. INO’s [@Biotechnology] market capitalization is $75.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $308.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 0 FA rating(s) are green whileINO’s FA Score has 0 green FA rating(s).

  • BCYC’s FA Score: 0 green, 5 red.
  • INO’s FA Score: 0 green, 5 red.
According to our system of comparison, INO is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 5 TA indicator(s) are bullish while INO’s TA Score has 5 bullish TA indicator(s).

  • BCYC’s TA Score: 5 bullish, 5 bearish.
  • INO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, INO is a better buy in the short-term than BCYC.

Price Growth

BCYC (@Biotechnology) experienced а -4.32% price change this week, while INO (@Biotechnology) price change was +8.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.95%. For the same industry, the average monthly price growth was +32.23%, and the average quarterly price growth was +16.56%.

Reported Earning Dates

BCYC is expected to report earnings on Jul 31, 2025.

INO is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (+1.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCYC($506M) has a higher market cap than INO($75.5M). INO YTD gains are higher at: 15.730 vs. BCYC (-47.786). INO has higher annual earnings (EBITDA): -93.37M vs. BCYC (-200.61M). BCYC has more cash in the bank: 793M vs. INO (68.4M). BCYC has less debt than INO: BCYC (8.33M) vs INO (11.3M). BCYC has higher revenues than INO: BCYC (25.7M) vs INO (283K).
BCYCINOBCYC / INO
Capitalization506M75.5M670%
EBITDA-200.61M-93.37M215%
Gain YTD-47.78615.730-304%
P/E RatioN/AN/A-
Revenue25.7M283K9,081%
Total Cash793M68.4M1,159%
Total Debt8.33M11.3M74%
FUNDAMENTALS RATINGS
BCYC vs INO: Fundamental Ratings
BCYC
INO
OUTLOOK RATING
1..100
7375
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9162
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
3547

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (50) in the null industry is in the same range as INO (50) in the Medical Specialties industry. This means that BCYC’s stock grew similarly to INO’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as INO (100) in the Medical Specialties industry. This means that BCYC’s stock grew similarly to INO’s over the last 12 months.

BCYC's SMR Rating (100) in the null industry is in the same range as INO (100) in the Medical Specialties industry. This means that BCYC’s stock grew similarly to INO’s over the last 12 months.

INO's Price Growth Rating (62) in the Medical Specialties industry is in the same range as BCYC (91) in the null industry. This means that INO’s stock grew similarly to BCYC’s over the last 12 months.

INO's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as BCYC (100) in the null industry. This means that INO’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCINO
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 15 days ago
82%
Bullish Trend 6 days ago
77%
Declines
ODDS (%)
Bearish Trend 8 days ago
86%
Bearish Trend 13 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CDWCX12.090.28
+2.37%
American Funds Dvlpg Wld Gr&Inc 529C
NBNAX15.05N/A
N/A
Neuberger Berman International Sel A
LMSAX37.02N/A
N/A
ClearBridge Small Cap A
VSEQX36.08N/A
N/A
Vanguard Strategic Equity Inv
FCAEX12.31N/A
N/A
Fidelity Climate Action

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with INO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+1.11%
INO - BCYC
57%
Loosely correlated
+6.74%
XNCR - BCYC
55%
Loosely correlated
-1.66%
RPTX - BCYC
51%
Loosely correlated
+0.71%
RLAY - BCYC
50%
Loosely correlated
+2.48%
RCUS - BCYC
45%
Loosely correlated
+1.39%
More

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with RPTX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then RPTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
+6.74%
RPTX - INO
59%
Loosely correlated
+0.71%
BCYC - INO
57%
Loosely correlated
+1.11%
AXON - INO
53%
Loosely correlated
+1.41%
ARRY - INO
52%
Loosely correlated
-13.80%
ONCO - INO
50%
Loosely correlated
+2.23%
More